Search alternatives:
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
significant all » significant anti (Expand Search), significant gap (Expand Search), significant _ (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search), step decrease (Expand Search)
all decrease » small decrease (Expand Search), a decrease (Expand Search), fold decrease (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
significant all » significant anti (Expand Search), significant gap (Expand Search), significant _ (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search), step decrease (Expand Search)
all decrease » small decrease (Expand Search), a decrease (Expand Search), fold decrease (Expand Search)
-
201
-
202
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
-
212
-
213
-
214
-
215
-
216
-
217
-
218
Data Sheet 1_Ribosomal protein L9 is a potential therapeutic target for B-ALL through the activation of the p53 signaling pathway.docx
Published 2025“…In this study, we observed a significant upregulation of RPL9 in human B-ALL cells compared to normal B cells, suggesting RPL9’s potential key role in B-ALL progression. …”
-
219
Table 1_Gender difference in the association between composite dietary antioxidant index and all-cause mortality.docx
Published 2025“…The restricted cubic spline revealed that the hazard ratio (HR) of all-cause mortality decreased significantly with increasing CDAI. …”
-
220
Table 2_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx
Published 2025“…Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I<sup>2</sup> = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I<sup>2</sup> = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I<sup>2</sup> = 65.5%). …”